Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

Cloudbreak Therapeutics, LLC (Industry)
Overall Status
Not yet recruiting ID
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary



Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.


3 months of TID treatment.

Treatment Groups, Dosing, and Treatment Regimen:

Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

Condition or DiseaseIntervention/TreatmentPhase
Phase 2

Study Design

Study Type:
Anticipated Enrollment :
90 participants
Intervention Model:
Parallel Assignment
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Official Title:
A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
Anticipated Study Start Date :
Sep 5, 2021
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Placebo Comparator: CBT-006

Drug: CBT-006

Experimental: 2.5% CBT-006

Drug: CBT-006

Experimental: 10% CBT-006

Drug: CBT-006

Outcome Measures

Primary Outcome Measures

  1. Incidence of treatment-emergent adverse events [3 months]

    Visual acuity, biomicroscopy, intraocular pressure, ophthalmoscopy

Secondary Outcome Measures

  1. Ocular discomfort score (0-4) [3 months]

    Change of the ocular discomfort score from baseline (Day 1) at Week 12; Score 0 is the most comfortable and 4 is the least comfortable

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Diagnosed with MGD in both eyes and meet the following:
  1. Ocular discomfort Score (ODS) ≥ 2 (No discomfort = 0, slight discomfort = 1, mild discomfort = 2, moderate discomfort = 3, severe discomfort = 4)

  2. Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories

  3. Total Cornea staining grade ≥ 3 (NEI scheme with max score = 15)

  4. Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid (0-3 scale with max total = 18).

  5. TBUT ≤ 5 s

  6. Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye

  7. BCVA LogMAR ≥ +0.7 in each eye

  • All patients of both genders ≥ 18 years

  • Willing to withhold the use of artificial tears and lubricants during the treatment phase;

  • Able to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion Criteria:
  • Uncontrolled systemic disease in the opinion of the Investigator

  • Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness

  • History of ocular herpes disease in either eye

  • Incisional ocular surgery within 6 months or ocular laser surgery within 3 months

  • Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening

  • Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.)

  • Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.)

  • Active rosacea involving the eyelids within 60 days of screening

  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study

  • Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study

  • Female patients who are pregnant, nursing, or planning a pregnancy during the study

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Cloudbreak Therapeutics, LLC


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Cloudbreak Therapeutics, LLC Identifier:
Other Study ID Numbers:
  • CBT-CS102
First Posted:
May 12, 2021
Last Update Posted:
Jul 28, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Jul 28, 2021